Selenium in the treatment of autoimmune thyroiditis
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
We recently conducted a prospective, placebo‐controlled clinical study, where we could demonstrate, that a substitution of 200 μg sodium selenite for three months in patients with autoimmune thyroiditis reduced thyroid peroxidase antibody (TPO‐Ab) concentrations significantly. Forty‐seven patients from the initially 70 patients agreed to participate in a follow‐up cross‐over study for further six months. One group (n = 13), which initially received selenium continued to take 200 μg sodium selenite (Se‐Se), one group stopped taking selenium (Se‐0) ( n = 9), another group which received placebo started to take 200 μg selenium (n = 14) (Plac‐Se) and the last group was without selenium substitution (Plac‐0) (n = 11). TPO‐Ab concentrations were measured at beginning and the end of the study. In the Se‐Se group, the TPO‐Ab concentrations further significantly p = 0.004) decreased from 625 ± 470 U/ml to 354 ± 321 U/ml, in the Se‐0 group the TPO‐Ab concentrations increased significantly p = 0.017) from 450 ± 335 to 708 ± 313 U/ml. In the placebo group, the TPO‐Ab concentrations in those patients who were followed without selenium substitution were unchanged (1351 ± 940 vs. 1724 ± 1112 U/ml, p = 0.555). In contrast, the patients who received 200 μg sodium selenite after placebo, the TPO‐Ab concentrations decreased significantly (p = 0.029) from 1182 ± 723 to 643 ± 477 U/ml.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The importance of selenium to human health
Rayman, M. P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02490-9 · Cited by 4,163
Gärtner, R., Gasnier, B. C. H., Dietrich, J. W., Krebs, B., & Angstwurm, M. W. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8421 · Cited by 389
Cited by
Selenium and endocrine systems
Beckett, G. J., & Arthur, J. R. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.05971 · Cited by 513
Negro, R., Greco, G., Mangieri, T., Pezzarossa, A., Dazzi, D., & Hassan, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1821 · Cited by 368
Duntas, L. H., & Benvenga, S. (2015) · Endocrine · doi:10.1007/s12020-014-0477-6 · Cited by 358
Selenium and Thyroid Disease: From Pathophysiology to Treatment
Ventura, M., Melo, M., & Carrilho, F. (2017) · International Journal of Endocrinology · doi:10.1155/2017/1297658 · Cited by 337
Selenium in thyroid disorders—essential knowledge for clinicians
Winther, K. H., Rayman, M. P., Bonnema, S. J., & Hegedüs, L. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0311-6 · Cited by 288
“(2015)87 Italy 60 (20/20/20) SeMet (80 μg/day) versus SeMet (160 μg/day) versus placebo 12 months None TSH, T3, T4, TPO- Ab, thyroglobulin- Ab, CXCL9, CXCL10, CXCL11, UL , HRQL No effects on TPO-Ab or UL , but downregulation of CXCL9 and CXCL10 Pirola et al.”
BackgroundInfluentialOtt, J., Promberger, R., Kober, F., Neuhold, N., Tea, M., Huber, J. C., & Hermann, M. (2011) · Thyroid · doi:10.1089/thy.2010.0191 · Cited by 190
Selenium supplementation for Hashimoto's thyroiditis: summary of a Cochrane systematic review
van Zuuren, E. J., Albusta, A. Y., Fedorowicz, Z., Carter, B., & Pijl, H. (2014) · European Thyroid Journal · doi:10.1159/000356040 · Cited by 65
Metadata
- Authors
- Gärtner, R., & Gasnier, B. C. H.
- Venue
- BioFactors
- Publisher
- Wiley
- Published
- 2003-01
- Volume
- 19
- Issue
- 3-4
- Pages
- 165-170
- ISSN
- 0951-6433 (ISSN-L)
- 1872-8081
- OpenAlex
- W2159254479
- Cited by
- 98
- References
- 2
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.